Should a transjugular intrahepatic portosystemic shunt (TIPS) be placed in a patient with non‑cirrhotic portal fibrosis (NCPF) who has recurrent variceal bleeding despite optimal secondary prophylaxis or refractory ascites, and what are the recommended stent size, target portosystemic pressure gradient, and post‑procedure management?

TIPS in Non-Cirrhotic Portal Fibrosis (NCPF)

TIPS can be considered as a treatment option for patients with non-cirrhotic portal fibrosis (NCPF) who have recurrent variceal bleeding despite optimal secondary prophylaxis or refractory ascites, though the evidence base is limited and the role remains unclear according to major guidelines.

Evidence Quality and Guideline Position

The 2020 BSG/BASL/BSIR guidelines explicitly state that the role of TIPS in idiopathic non-cirrhotic portal hypertension (which includes NCPF) is "not clear" 1. This represents the highest quality guideline evidence available, but it acknowledges significant uncertainty. The 2024 French guidelines do not specifically address NCPF as a distinct entity 2.

However, recent case reports demonstrate feasibility: a 2026 case report showed successful TIPS placement for porto-sinusoidal vascular disorder (PSVD, which encompasses NCPF) with resolution of refractory ascites and improvement in varices, though complications including hepatic ischemia, portal vein thrombosis, and hepatic encephalopathy occurred but were manageable 3.

When to Consider TIPS in NCPF

Indications (Based on Extrapolation from Cirrhotic Guidelines):

For Recurrent Variceal Bleeding:

• After failure of combined endoscopic band ligation (EBL) and non-selective beta-blockers (NSBB) 1
• Acute variceal bleeding unresponsive to endoscopy and pharmacotherapy 1
• Recurrent bleeding despite optimal secondary prophylaxis 4

For Refractory Ascites:

• Persistent ascites despite maximum diuretic therapy and repeated large-volume paracentesis 1
• Though evidence for survival benefit is lacking even in cirrhosis 1

Critical Caveat for NCPF:

Unlike cirrhosis, NCPF patients typically have preserved hepatic synthetic function. This theoretically makes them better candidates for TIPS as they should tolerate the procedure better and have lower risk of post-TIPS liver failure 3, 4.

Pre-Procedure Evaluation

Mandatory assessments before TIPS in NCPF:

1. Cross-sectional imaging (CT/MRI) to evaluate liver and portal vein anatomy 1
2. Liver and kidney function tests 1
3. Coagulation studies - use thromboelastography rather than INR for decision-making 1
4. Cardiac function assessment (echocardiography) 1
5. Nutritional assessment 1
6. Hepatic encephalopathy risk stratification 1
7. Exclude prothrombotic conditions that might complicate NCPF 4

Technical Specifications

Stent Type:

Use PTFE-covered stents exclusively - they have superior patency rates compared to bare metal stents 1, 5

Stent Size:

Start with smaller diameter stents (6-8mm) to reduce risk of hepatic encephalopathy and cardiac complications 1, 5. The stent can be dilated later if needed. This staged approach is particularly important in NCPF where baseline liver function is preserved 5.

Target Portosystemic Pressure Gradient (PSG):

For variceal bleeding:

• Reduce PSG to <12 mmHg OR
• Achieve ≥20% reduction from baseline 1, 5

For ascites/other indications:

• Target must balance efficacy against hepatic encephalopathy risk
• Individualize based on hemodynamic response 1

Variceal Embolization:

Consider concurrent variceal embolization if large varices persist on portography after adequate PSG reduction 1, 5

Post-Procedure Management

Immediate Surveillance:

• Doppler ultrasound at 1 week post-TIPS in all patients with prothrombotic conditions or suspected dysfunction 1
• Early ultrasound particularly important in NCPF given potential underlying prothrombotic states 4

Long-term Surveillance:

• Doppler ultrasound every 6-12 months 1
• More frequent monitoring (every 3-6 months) if prothrombotic conditions present 2

Anticoagulation:

Consider long-term anticoagulation in NCPF patients given:

• Potential underlying prothrombotic disorders 4
• Risk of TIPS thrombosis
• Though specific guidelines for NCPF are lacking

Hepatic Encephalopathy Prophylaxis:

• Lactulose as first-line
• Rifaximin for breakthrough or recurrent episodes
• Monitor closely as NCPF patients may have lower baseline risk given preserved hepatic function 3

Key Differences from Cirrhotic TIPS

1. Better baseline hepatic reserve - NCPF patients tolerate TIPS better theoretically 3, 4
2. Different natural history - predominantly variceal bleeding with transient ascites rather than progressive liver failure 4
3. Prothrombotic considerations - higher vigilance for portal vein thrombosis 4
4. Potential for liver transplantation - reserve for those developing hepatic dysfunction 4

Contraindications (Absolute)

• Severe right heart failure
• Severe pulmonary hypertension
• Uncontrolled systemic infection/sepsis
• Extensive hepatocellular carcinoma
• Complete portal vein thrombosis (relative - may attempt recanalization) 1

Common Pitfalls

1. Assuming NCPF behaves like cirrhosis - it doesn't; preserved liver function changes risk-benefit
2. Oversizing the stent initially - start small to minimize encephalopathy risk 5
3. Inadequate thrombophilia workup - NCPF often has prothrombotic associations 4
4. Neglecting cardiac assessment - sudden increase in venous return can precipitate heart failure 1

Practical Algorithm for NCPF

Step 1: Confirm NCPF diagnosis (liver biopsy if needed)
Step 2: Optimize medical therapy (NSBB + endoscopic therapy for varices; diuretics for ascites)
Step 3: If failure of medical therapy → multidisciplinary discussion
Step 4: Complete pre-TIPS evaluation (above checklist)
Step 5: If suitable candidate → TIPS with covered stent, starting at 6-8mm diameter
Step 6: Target PSG <12 mmHg for bleeding, individualize for ascites
Step 7: Consider variceal embolization if large varices persist
Step 8: Doppler ultrasound at 1 week, then every 6 months
Step 9: HE prophylaxis and close monitoring

3, 4